Stockscreener 앱 받기
0.856
3.88%
0.032
시간 외 거래:
.83
-0.026
-3.04%
전일 마감가:
$0.824
열려 있는:
$0.837
하루 거래량:
314.33K
Relative Volume:
0.60
시가총액:
$19.15M
수익:
-
순이익/손실:
$-38.85M
주가수익비율:
-0.2958
EPS:
-2.8936
순현금흐름:
$-44.99M
1주 성능:
+3.14%
1개월 성능:
-11.04%
6개월 성능:
-38.42%
1년 성능:
-14.40%
1일 변동 폭
$0.8328
$0.8717
1주일 범위
$0.78
$0.8717
52주 변동 폭
$0.63
$2.48
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
명칭
Citius Pharmaceuticals Inc
전화
(908) 967-6676
주소
11 COMMERCE DRIVE, CRANFORD, NJ
Compare CTXR vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
0.856 | 18.44M | 0 | -38.85M | -44.99M | -2.8936 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-30 | 업그레이드 | D. Boral Capital | Hold → Buy |
| 2021-11-30 | 개시 | Maxim Group | Buy |
Citius Pharmaceuticals Inc 주식(CTXR)의 최신 뉴스
Can Citius Pharmaceuticals Inc lead its sector in growth2026 Weekly Recap & Technical Confirmation Trade Alerts - baoquankhu1.vn
Risk Report: What is Citius Pharmaceuticals Incs 5 year growth outlook2026 Technical Patterns & Weekly Breakout Stock Alerts - baoquankhu1.vn
Retail Trends: Is Citius Pharmaceuticals Inc in a long term uptrend2026 Snapshot & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Citius Pharmaceuticals accelerates clinical momentum for LYMPHIR as oncology interest climbs - Traders Union
Support Test: What is Citius Pharmaceuticals Incs 5 year growth outlookWeekly Gains Report & Safe Capital Allocation Plans - baoquankhu1.vn
Citius Pharmaceuticals, Inc. Files Form 8-K Current Report with SEC on April 6, 2026 - Minichart
Trading Recap: Why is Cincinnati Financial Corporation stock going upBull Run & AI Forecasted Entry/Exit Points - baoquankhu1.vn
EPS Watch: What is Citius Pharmaceuticals Incs 5 year growth outlookTrade Analysis Report & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Citius Pharmaceuticals elects board members and ratifies auditor at annual meeting - Investing.com Australia
Citius Pharmaceuticals elects board members and ratifies auditor at annual meeting By Investing.com - Investing.com South Africa
Citius Pharmaceuticals Announces 2026 Annual Stockholder Meeting Results - TipRanks
Shareholders keep Citius (NASDAQ: CTXR) board and approve Wolf as auditor - Stock Titan
CTXR SEC FilingsCitius Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
CTXR Technical Analysis & Stock Price Forecast - Intellectia AI
Breakouts Watch: What is Citius Pharmaceuticals Incs 5 year growth outlookTrade Risk Report & Fast Entry and Exit Trade Plans - baoquankhu1.vn
CTXR Stock Chart | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
CTOR Stock Price, Quote & Chart | CITIUS ONCOLOGY INC (NASDAQ:CTOR) - ChartMill
Citius Oncology highlights early LYMPHIR commercial traction, expansion - TipRanks
Citius Oncology advances LYMPHIR launch and global expansion - TipRanks
Bond Watch: Is Citius Pharmaceuticals Inc in a long term uptrend2026 Performance Recap & Technical Pattern Recognition Alerts - baoquankhu1.vn
Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting Early Adoption and Expanding Clinical Development - Finviz
Citius Pharmaceuticals subsidiary reports strong early uptake and broad payer coverage for LYMPHIR launch - TradingView — Track All Markets
Citius Oncology (CTXR) details early LYMPHIR launch uptake and $400M CTCL market - Stock Titan
Early LYMPHIR launch traction at Citius Oncology (Nasdaq: CTOR) - Stock Titan
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Hi - GuruFocus
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development - PR Newswire
Citius Pharmaceuticals Inc (47N0.MU) balance sheet - Yahoo Finance UK
RSI Check: Is Citius Pharmaceuticals Inc stock good for income investors2026 Sector Review & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Citius Pharmaceuticals Inc (47N0.MU) insider ownership and holdings - Yahoo Finance UK
Citius Pharmaceuticals Inc (47N0.MU) recent insider transactions - Yahoo Finance UK
Rate Hike: Is Citius Pharmaceuticals Inc a cyclical or defensive stock2026 News Drivers & Low Risk Entry Point Guides - baoquankhu1.vn
CTXR Stock Price, Quote & Chart | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
Citius Pharmaceuticals to present CTCL clinical experience at USCLC Annual Workshop - tradersunion.com
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts - BioSpace
Citius Oncology to Participate in USCLC Annual Workshop 2026, Hi - GuruFocus
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions with Leading Cutaneous Lymphoma Experts - Finviz
Doctors treating rare skin lymphoma will discuss Citius drug LYMPHIR - Stock Titan
Aug Mood: Can Citius Pharmaceuticals Inc withstand a market correctionEarnings Beat & Long-Term Growth Plans - baoquankhu1.vn
Downgrade Watch: Is Citius Pharmaceuticals Inc benefiting from interest rate changesPortfolio Gains Summary & Fast Gain Stock Tips - baoquankhu1.vn
If You Invested $1,000 in Citius Pharmaceuticals Inc (CTXR) - Stock Titan
Macro Review: Should I buy Citius Pharmaceuticals Inc stock nowSell Signal & Growth Oriented Trading Recommendations - baoquankhu1.vn
Citius Oncology inks exclusive European distribution pact with Uniphar - MSN
Ideas Watch: Is Euroholdings Ltd stock trending bullishEarnings Recap Report & Weekly High Return Stock Opportunities - baoquankhu1.vn
Energy Moves: Does Citius Pharmaceuticals Inc align with a passive investing strategyMarket Trend Summary & AI Driven Price Forecasts - baoquankhu1.vn
D Boral Capital maintains Citius Pharmaceuticals (CTXR) buy recommendation - MSN
Activity Recap: Is Citius Pharmaceuticals Inc a potential multi baggerIPO Watch & Stepwise Trade Execution Plans - baoquankhu1.vn
CTORCitius Oncology, Inc. Latest Stock News & Market Updates - Stock Titan
Activity Recap: Is Citius Pharmaceuticals Inc stock good for income investors2026 Historical Comparison & AI Forecast Swing Trade Picks - baoquankhu1.vn
CTOR Stock Price and Chart — NASDAQ:CTOR - TradingView — Track All Markets
Zevra Therapeutics, Inc.Common Stock (NQ: ZVRA - The Chronicle-Journal
CTXR: Citius Pharmaceuticals Receives Consistent 'Buy' Rating fr - GuruFocus
Citius Pharmaceuticals Inc (CTXR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):